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Abstract
Background: Persons living with HIV (PLWH) have an elevated risk for certain types of cancer. 
With modern antiretroviral therapy, PLWH are aging and cancer rates are changing.
Objective: To project cancer incidence rates and burden (number of new cancer diagnoses) 
among adult PLWH in the United States through 2030.
Design: Descriptive.
Setting: HIV/AIDS Cancer Match Study to project cancer rates and HIV Optimization and 
Prevention Economics model to project HIV prevalence.
Participants: HIV-infected adults.
Measurements: Projected cancer rates and burden among HIV-infected adults in the United 
States by age during 2006 to 2030 for AIDS-defining cancer (ADC; that is, Kaposi sarcoma, non-
Hodgkin lymphoma, and cervical cancer) and certain types of non–AIDS-defining cancer 
(NADC). All other cancer types were combined.
Results: The proportion of adult PLWH in the United States who are aged 65 years or older is 
projected to increase from 8.5% in 2010 to 21.4% in 2030. Age-specific rates are projected to 
decrease through 2030 across age groups for Kaposi sarcoma, non-Hodgkin lymphoma, cervical 
cancer, lung cancer, Hodgkin lymphoma and other cancer types combined, and among those aged 
65 years or older for colon cancer. Prostate cancer rates are projected to increase. The estimated 
total cancer burden in PLWH will decrease from 8150 cases in 2010 (2730 of ADC and 5420 of 
NADC) to 6690 cases in 2030 (720 of ADC and 5980 of NADC). In 2030, prostate cancer (n = 
1590) and lung cancer (n = 1030) are projected to be the most common cancer types.
Limitation: Projections assume that trends in current cancer incidence rates, HIV transmission, 
and survival will continue.
Conclusion: The cancer burden among PLWH is projected to shift, with prostate and lung 
cancer expected to emerge as the most common types by 2030. Cancer will remain an important 
comorbid condition, and expanded access to HIV therapies and cancer prevention, screening, and 
treatment is needed.
TOC summary
Persons living with HIV (PLWH) have a greatly improved life expectancy due to the introduction 
of potent antiretroviral drug therapies. Projecting future rates and number of incident diagnoses of 
both AIDS-defining and non–AIDS defining cancer in PLWH is important in order to inform the 
design of programs for prevention, screening, and treatment.
Mortality among persons living with HIV (PLWH) has been drastically reduced by treatment 
with effective antiretroviral therapy (ART), which suppresses HIV replication and improves 
immune function (1). A person newly diagnosed with HIV in North America is expected to 
live to his or her early 70s with treatment (2). This increased longevity has shifted the age 
distribution of U.S. PLWH from 27% aged 50 years or older in 2006 to 45% in 2014 (3, 4), 
and the fraction of older PLWH is expected to continue growing.
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Antiretroviral therapy has also reduced the risk for certain types of cancer known to occur in 
excess among PLWH, particularly AIDS-defining cancer (ADC; that is, Kaposi sarcoma 
[KS], certain types of non-Hodgkin lymphoma [NHL], and cervical cancer) (5, 6). The 
decrease in ADC rates combined with the growth and aging of the U.S. HIV population has 
resulted in a shift from predominantly ADC in the 1980s (7) to predominantly non–AIDS-
defining cancer (NADC) in 2010 and a net increase in incident cancer diagnoses (that is, 
cancer burden) over time (8). The most frequent types of NADC in PLWH include those that 
occur at a higher rate among PLWH (such as anal cancer, liver cancer, oral cavity and 
pharyngeal cancer, and Hodgkin lymphoma [which are caused by viral co-infections] and 
lung cancer) and those that are common in the general population (such as prostate, breast, 
and colon cancer) (8).
The cancer burden among U.S. PLWH will continue to evolve as cancer incidence rates and 
the size and demographics of the HIV population change over time. We used population-
based data on HIV and cancer to project cancer incidence rates in the adult HIV population 
and the HIV Optimization and Prevention Economics (HOPE) model to forecast the number 
of PLWH through 2030. We then calculated projected cancer burden. These results highlight 
anticipated reductions in cancer burden with continued and expanded access to ART and 
identify types of cancer expected to predominate in the future, informing public health 
research and the prioritization of cancer prevention, early detection, and treatment.
Methods
Cancer Incidence Rate Projections
Cancer incidence in PLWH was estimated from the National Cancer Institute’s HIV/AIDS 
Cancer Match Study, a record linkage study of HIV and cancer registries in 9 U.S. regions 
(www.hivmatch.cancer.gov). This analysis considered the most common cancer types among 
PLWH: KS; NHL; Hodgkin lymphoma; and cervical, anal, lung, liver, oral cavity and 
pharyngeal, prostate, breast, and colon cancer (9), classified on the basis of the International 
Classification of Diseases for Oncology, Third Edition (10). All other cancer sites were 
analyzed together as “other types of cancer.”
We modeled trends in cancer incidence rates during 2000 to 2012 to project rates during 
2013 to 2030. Follow-up began on whichever occurred last: 1 January 2000, the beginning 
of cancer registry coverage, or the first of HIV report date or AIDS diagnosis date. It ended 
at either death or the end of cancer registry coverage. Cancer incidence rates among adults 
were estimated in strata defined by calendar year and age group (18 to 24 years, 25 to 34 
years, 35 to 44 years, 45 to 64 years, and 65 years or older), and by risk group for KS and 
anal cancer (men who have sex with men [MSM] and non-MSM) and liver cancer (persons 
who inject drugs [PWID] and non-PWID). Age groups were combined on the basis of the 
number of observed cancer cases in each group (Appendix Table 1, available at Annals.org). 
Children and (for some cancer sites) younger adults were excluded because cancer in these 
groups was too rare to model. We used joinpoint regression (11) to identify statistically 
significant changes in the slope of time trends (i.e., joinpoints). We identified 3 cancer 
incidence trends with significant joinpoints. For NHL, we restricted our analysis to years 
after the joinpoint (2002 and later). However, because follow-up data were limited for anal 
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cancer in MSM (joinpoint, 2009) and liver cancer in PWID (joinpoint, 2005), we used 2000 
to 2012 to analyze these cancer sites (Appendix, available at Annals.org).
We used Poisson regression to estimate the annual change in cancer incidence rates during 
2000 to 2012. Estimated β-coefficients and variance–covariance matrixes were then used to 
project cancer incidence rates and 95% CIs for 2013 to 2030. Age group was included as a 
term in the model unless a significant interaction (P ≤ 0.10) between age group and calendar 
year was present, in which case age group–specific models were estimated. If no statistically 
significant trend was observed during 2000 to 2012, modeled 2012 rates were applied for 
2013 to 2030. For cancer types known to be elevated in PLWH, we assumed a priori that 
future cancer rates would never be lower than those observed in the general population. 
Therefore, for these cancer types, any projected rate that was lower than the 2013 age-
specific rate in the SEER-18 (Surveillance, Epidemiology, and End Results–18) data (12) 
(used as a proxy for the U.S. general population) was reset to the SEER rate. Likewise, 
because PLWH have a lower risk for prostate, breast, and colon cancer for unclear reasons 
(9, 13), we assumed that the age-specific rates of these cancer types would never exceed 
those in SEER-18 (Appendix). Rates standardized by age (and by risk group for KS, anal 
cancer, and liver cancer) were estimated for 2006 to 2030 by standardizing each year to the 
2010 modeled HIV population (see below).
HIV Population Estimates
The number of PLWH in the United States during 2006 to 2030 was estimated with the 
dynamic, compartmental HOPE model, which simulates the sexually active population of 
the United States beginning in 2006 (Appendix) (14, 15). In brief, the population is stratified 
into 195 subpopulations by transmission group (gay, bisexual, and other MSM [collectively 
called MSM]; PWID; or heterosexuals); sex (male or female); race/ethnicity (black; 
Hispanic or Latino; or combined white and other racial/ethnic groups, of which whites 
comprised 89%); age group (13 to 17 years, 18 to 24 years, 25 to 34 years, 35 to 44 years, 
45 to 64 years, or 65 years or older); male circumcision status (circumcised or 
uncircumcised); and HIV risk level (low or high), defined for this model on the basis of 
previously published methods. The force of HIV infection, or the rate at which susceptible 
persons acquire it, is a function of HIV prevalence among their partners and transmission 
risk from sexual and needle contacts with infected partners (16, 17). The technical report of 
a previous article based on the HOPE model (15) provides the 2 mixing matrixes that 
represent the distributions of sexual and needle-sharing partners. The HOPE model assumes 
continued improvement in HIV care based on an observed trend during 2009 to 2012, 
resulting in longer survival of PLWH and reduced HIV transmission. Uncertainty estimates 
for each calendar year were generated (Appendix).
Cancer Burden Projections
The number of incident cancer diagnoses (that is, cancer burden) per calendar year was 
estimated by multiplying incidence rates specific to age and risk groups by numbers of 
PLWH in corresponding strata. Uncertainty estimates were generated by multiplying the 
lower and upper 95% CIs from the incidence rates by the minimum and maximum numbers 
of PLWH, respectively (Appendix).
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We compared the cancer burden estimates in 2030 in 2 scenarios: assuming a flat projection 
of the 2012 cancer incidence rate and assuming that the age distribution (but not population 
size) in 2030 remained the same as in 2012. These approaches provide insight into the 
independent effects that changing cancer incidence rates and age structure of the HIV 
population have on the estimated burden.
For comparison, we also present the proportion of the total cancer burden contributed by 
each cancer site among PLWH during 2010 and 2030 and in the general U.S. population in 
2010, with data from SEER-18.
Results
Cancer Incidence Rates Among Adult PLWH, 2000 to 2030
Between 2000 and 2012, a total of 23 907 cases of cancer occurred among 463 300 HIV-
infected adults in the HIV/AIDS Cancer Match Study. During that time, observed incidence 
rates decreased significantly (P < 0.05) for KS, NHL, cervical cancer, anal cancer (among 
MSM), lung cancer, Hodgkin lymphoma, and other cancer types across all age groups and 
for colon cancer among only those aged 65 years or older. Incidence rates of NHL, cervical 
cancer, and lung cancer are projected to decrease to the general population rates for some 
age groups (Appendix Table 1 and Appendix Figure 1, available at Annals.org). Prostate 
cancer rates increased significantly among men aged 35 to 44 years and 45 to 64 years, 
reaching general population rates, but not among men aged 65 years or older. No significant 
trends (P ≥ 0.05) were observed across age groups for rates of anal cancer among non-MSM, 
liver cancer among PWID and non-PWID, oral cavity and pharyngeal cancer, and breast 
cancer, or among those aged 25 to 64 years for rates of colon cancer (Appendix Table 1).
Age-standardized incidence rates are projected to decrease during 2006 to 2030 for 7 of 11 
cancer sites. This includes all 3 types of ADC and 4 of 8 types of NADC but excludes 
breast, oral cavity and pharyngeal, and liver cancer, for which rates are expected to remain 
stable, and prostate cancer, for which rates will increase (Figure 1, A to C). We project the 
largest relative declines (approximately 80%) in age-standardized incidence rates per 100 
000 PLWH for KS (129.8 to 29.0 cases), NHL (184.3 to 36.1 cases), and cervical cancer 
(61.0 to 10.2 cases).
Estimated Number of Adult PLWH, 2006 to 2030
The number of adult PLWH in the United States is projected to increase from 1.06 million in 
2006 to 1.17 million in 2018 before decreasing to 1.09 million in 2030 (Figure 2). This 
projected decrease is caused by declines in HIV incidence rates due to reduced transmission 
resulting from increases in the proportion of PLWH who know they are infected, receive 
effective treatment, and are virally suppressed (15). Of note, the age distribution of PLWH is 
expected to shift substantially between 2010 and 2030: The proportion of adult PLWH aged 
65 years or older will nearly triple from 8.5% to 21.4%, and the proportion aged 45 to 64 
years will increase from 39.4% to 47.7% (Appendix Table 2). The sex and racial/ethnic 
distributions are expected to remain roughly the same, and the fraction of adult PLWH who 
are MSM is projected to increase slightly (from 55.4% in 2010 to 61.0% in 2030). Appendix 
Shiels et al. Page 5
Ann Intern Med. Author manuscript; available in PMC 2019 January 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Table 3 (available at Annals.org) gives the minimum and maximum HIV population 
estimates for each calendar year.
Estimated Cancer Burden Among Adult PLWH, 2006 to 2030
In 2010, PLWH had an estimated 8150 cancer cases (uncertainty estimate, 7280 to 9210 
cases), including 2730 of ADC (uncertainty estimate, 2440 to 3100 cases) and 5420 of 
NADC (uncertainty estimate, 4850 to 6120 cases) (Table). The total is expected to decrease 
to 6690 cases (uncertainty estimate, 4950 to 9060 cases) in 2030, driven by strong decreases 
in ADC but with modest increases in NADC (Figure 3). When examined by age, 1500 fewer 
cases are expected among PLWH younger than 45 years and 40 additional cases among 
PLWH aged 45 years or older in 2030 compared with 2010 (Figure 3).
The composition of the cancer burden is expected to shift substantially over time (Figure 4). 
In 2010, the most common cancer types were NHL (1490 cases [uncertainty estimate, 1350 
to 1660 cases]), KS (1120 cases [uncertainty estimate, 990 to 1290 cases]), and lung cancer 
(830 cases [uncertainty estimate, 750 to 920 cases]). By 2020, prostate cancer is expected be 
the most common (1340 cases [uncertainty estimate, 1060 to 1660 cases]). In 2030, the most 
common cancer sites will be prostate (1590 cases [uncertainty estimate, 1240 to 1820 
cases]), lung (1030 cases [uncertainty estimate, 940 to 1090 cases]), and liver (480 cases 
[uncertainty estimate, 360 to 630 cases]). The largest decreases between 2010 and 2030 are 
estimated to occur for NHL (−1040 cases) and KS (−880 cases) and the largest increases for 
prostate (+840 cases), lung (+200 cases), and liver cancer (+120 cases). The expected cancer 
burden in 2030 among PLWH will remain different from the observed burden in the general 
population in 2010, with a higher fraction of liver cancer, anal cancer, and KS (Appendix 
Figure 2, available at Annals.org).
Influence of Cancer Incidence Rates and the Aging of the HIV Population on Cancer 
Burden
To assess the independent effect of changing incidence rates on cancer burden, we estimated 
the burden for 2030 using the generally higher 2012 incidence rates (fixing the HIV 
population demographics to the 2030 projection). The burden estimates produced by the 
2012 rates were 43% higher than those projected in the main analysis, including a 197% 
increase in ADC and a 24% increase in NADC (Figure 5). This pattern held for most cancer 
types, except for breast, liver, and oral cavity and pharyngeal cancer (that is, types that 
already had flat incidence projections) and prostate cancer. The largest differences in burden 
were observed for NHL and KS.
To assess the independent effect of aging of the HIV population, we estimated the 2030 
cancer burden using the generally younger age structure of the 2012 population (fixing the 
cancer incidence rates at the 2030 projections). Compared with the results from the main 
analysis, the cancer burden in 2030 would be 25% lower if the 2012 age structure were used. 
The total number of NADC cases would be 28% lower, whereas the total number of ADC 
cases would be 3% higher. Decreases in burden were seen for most cancer types except for 
cervical cancer, Hodgkin lymphoma, and KS; prostate and lung cancer had the largest 
decreases (Figure 5).
Shiels et al. Page 6
Ann Intern Med. Author manuscript; available in PMC 2019 January 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
Increased life expectancy among PLWH due to effective ART will result in further aging of 
the HIV population in the coming years. Concurrently, if recent trends in cancer incidence 
rates among PLWH continue, the incidence rates of many types of cancer will decrease 
through 2030; the largest declines are predicted for the 2 most common ADC types, NHL 
and KS. As a result, we forecast notable shifts in the number of incident cancer diagnoses 
(that is, cancer burden) among PLWH in the coming decade. The fraction of the cancer 
burden due to ADC will decrease from one third in 2010 to 11% in 2030, and the most 
common cancer types diagnosed among PLWH will shift from NHL and KS in 2010 to 
prostate and lung cancer in 2030.
Antiretroviral therapy has been the most effective means of reducing cancer burden in 
PLWH and will continue to be critical in the future. It suppresses HIV replication and 
reduces immunosuppression among PLWH, improving the immune system’s ability to 
control oncogenic viral infections (18). Because most types of ADC are caused by viral co-
infections (that is, human herpesvirus-8 causes KS, Epstein–Barr virus causes some types of 
NHL, and human papillomavirus [HPV] causes cervical cancer), ART has been particularly 
effective at reducing ADC incidence (5, 6, 19). If progress continues, ADC rates for all ages 
will continue to decrease, and rates of NHL (in older age groups) and cervical cancer will 
converge with those of the general population before 2030. Although KS and NHL rates in 
younger age groups will remain higher than those of the general population, declining rates 
will lead to a notable decrease in the number of these cancer cases through 2030.
The risks for anal, lung, liver, and oral cavity and pharyngeal cancer and Hodgkin lymphoma 
are elevated among PLWH compared with the general population (20, 21). Increased risk is 
likely driven by a combination of factors. First, PLWH have a higher burden of certain 
carcinogenic viruses, such as HPV and hepatitis B and C viruses. In addition, lack of viral 
control in the setting of immunosuppression increases cancer risk (that is, HPV causes anal 
cancer and some types of tonsil and oropharyngeal cancer, hepatitis B and C viruses cause 
liver cancer, and Epstein–Barr virus causes Hodgkin lymphoma). Finally, PLWH have a 
higher prevalence of some cancer risk factors, most notably cigarette smoking (18, 22). Of 
note, elevated risk for lung cancer is not entirely explained by smoking, and immune 
suppression, chronic lung inflammation, and pulmonary infections may contribute (23–25). 
Rates of prostate, breast, and colon cancer are actually lower in PLWH in some studies (9, 
21).
Between 2000 and 2012, we observed stable or decreasing incidence rates for most types of 
NADC, except prostate cancer among men aged 35 to 64 years. These trends are generally 
consistent with those reported in other recent studies (5, 26, 27). Furthermore, the risks for 
anal, lung, and liver cancer and Hodgkin lymphoma in U.S. PLWH have declined relative to 
those in the general population, supporting a role of ART in decreasing risk for these types 
of cancer (9). Of note, we project that rates of lung cancer will no longer be elevated among 
PLWH by 2030. Although lung cancer rates have declined significantly, we caution that our 
projection of a continued decline may not be realistic if the prevalence of smoking does not 
decrease substantially among PLWH (22).
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Quantifying both incidence rates and burden is important. Rates describe cancer risk among 
PLWH, whereas burden captures total number of diagnoses. Changes in incidence rates, 
population age structure, and population size all influence cancer burden. By holding the 
incidence rates or age structure constant on the basis of 2012 estimates in secondary 
analyses, we could assess how changes over time contributed to the projections in our main 
analyses. Decreasing incidence rates most notably affected the decreasing burden of KS, 
NHL, and cervical cancer. In contrast, the aging of U.S. PLWH resulted in a projected 
increase for many cancer types, most notably prostate and lung cancer. Although the cancer 
burden is projected to evolve, it will continue to differ from that in the general population, 
with a higher fraction of KS, liver cancer, and anal cancer.
The main strengths of this analysis were the data sources, which included high-quality data 
on cancer incidence in nearly 500 000 PLWH and U.S. HIV population estimates from the 
HOPE model developed by the Centers for Disease Control and Prevention. Our results 
should be interpreted under the assumption that trends in current cancer incidence, HIV 
transmission, and survival will continue through 2030, which we largely attribute to 
improvements in and wider use of ART. Of note, our analysis cannot account for any 
unexpected changes in HIV or cancer incidence. For example, interventions that have been 
recently introduced or may expand in the coming years could reduce future cancer risk and 
burden in PLWH (such as treatment of hepatitis C virus infection and screening for anal 
cancer). In contrast, unforeseen changes that reduce access to treatment of HIV infection 
(such as reductions in health insurance coverage) or increase HIV incidence (such as 
outbreaks due to increases in injection drug use) would increase the cancer burden among 
PLWH.
The main limitation is the uncertainty in the input parameters of the HOPE model, although 
modeled estimates closely matched HIV surveillance estimates for 2014 (28). For example, 
the latest 2014 estimates from the Centers for Disease Control and Prevention for persons 
aged 13 to 64 years were 1 107 700 cases for overall HIV prevalence and 37 600 cases for 
overall HIV incidence (28), and the model predictions were 1 042 140 and 35 761 cases, 
respectively, suggesting some predictive validity. We did uncertainty analyses by varying the 
calibrated parameters, and those results indicated robustness in prevalence estimates across 
potential calibration sets. We have attempted to quantify the uncertainty around our cancer 
burden estimates by combining information on the uncertainties in rate and population 
projections. In addition, power was limited for several strata, which may have resulted in 
trends being modeled as flat projections.
Although the number of cancer cases diagnosed among PLWH is projected to decrease, 
cancer will remain an important comorbid condition, and continued prevention efforts are 
needed. Increased access to effective ART will be critical in reducing future cancer burden 
in PLWH, and current recommendations advocate treatment of all PLWH, regardless of CD4 
count (29). Interventions focused on smoking cessation and treatment of hepatitis B and C 
virus infections could reduce the future burden of lung and liver cancer. Vaccination for 
HPV has been found to be safe and immunogenic in PLWH (30), and a clinical trial is 
currently evaluating vaccination in HIV-infected MSM for the prevention of HPV infection 
and anal intraepithelial neoplasia (ClinicalTrials.gov: NCT01209325).
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Future research and public health programs should also focus on early detection and 
treatment of cancer among PLWH. Some screen-detectable types (such as breast, lung, and 
cervical cancer) are more frequently diagnosed at advanced stages among PLWH, perhaps 
reflecting delayed diagnosis (31). Specific cervical cancer screening guidelines should be 
followed for HIV-infected women (32). For other types of cancer, screening strategies in 
PLWH receiving ART should reflect the same consideration of benefits, harms, and costs as 
in the general population. Of note, an ongoing clinical trial is addressing anal Papinocolau 
testing and treatment of precancerous lesions among PLWH (ClinicalTrials.gov: 
NCT02135419), and more research is needed on screening for lung cancer (low-dose 
computed tomography). Finally, cancer treatment and survival differ between PLWH and the 
general population, which emphasizes the need to incorporate PLWH into clinical trials and 
guidelines for cancer treatment (33–35).
In conclusion, we have shown that the number of incident cancer diagnoses (that is, cancer 
burden) among PLWH will shift substantially through 2030. The incidence rates of most 
cancer types will likely remain stable or decrease, with the largest declines for NHL and KS. 
In 2030, prostate and lung cancer are projected to be the most common types, followed by 
liver and anal cancer. Although the total burden of cancer among PLWH is expected to 
decrease by 18%, cancer will remain an important comorbid condition, and tailored public 
health programs focused on cancer prevention, screening, and treatment in PLWH are 
needed.
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Appendix:: Additional Details on Methods
HIV/AIDS Cancer Match Contributing Registries
The HIV/AIDS Cancer Match Study is a record linkage study of HIV and cancer registries 
in the United States (www.hivmatch.cancer.gov). Data from 8 U.S. states (Colorado, 
Connecticut, Georgia, Maryland, Michigan, New Jersey, New York, and Texas) and Puerto 
Rico were included in this analysis.
Joinpoint Analysis and Assessment of Heterogeneity by Registry
Joinpoint regression (11) was used to identify the presence of statistically significant 
changes in the slope of time trends in crude cancer incidence rates in each age and risk 
group stratum, and if a significant change was present, calendar years before the joinpoint 
were excluded from all analyses for that cancer site. Joinpoints were detected in 2002 for 
NHL among persons aged 35 to 44 years, in 2009 for anal cancer among MSM aged 45 
years or older, and in 2005 for liver cancer among PWID aged 65 years or older. Models for 
NHL were restricted to 2002 and later. Restricting anal and liver cancer models to start in 
2009 and 2005, respectively, resulted in too few cases; therefore, the full time period (2000 
to 2012) was used in these 2 projections. Of note, the joinpoint trends in the most recent 
period were not statistically significant for either of these cancer sites. In addition, data from 
2000 were excluded from Hodgkin lymphoma models because the rate in that year was 
extremely high.
For each cancer type, heterogeneity by registry was assessed by including an interaction 
term between registry and calendar year in the Poisson model. Significant heterogeneity was 
observed only for NHL and the other combined cancer category. After the registries with the 
most extreme trends (that is, Maryland for NHL and New Jersey for other types of cancer 
combined) were excluded, no notable differences in projected incidence rates were observed, 
so all registries were retained in the main analysis.
Comparison of Modeled and Projected Rates With General Population 
Rates
For types of cancer known to be more prevalent in HIV-infected people (KS; NHL; cervical, 
anal, lung, liver, and oral cavity and pharyngeal cancer; and Hodgkin lymphoma [9]), we 
assumed a priori that future cancer rates would never be lower than rates observed in the 
general population. Therefore, any projected rate that was lower than the age-specific rate 
observed for the U.S. general population, based on data from 18 cancer registries in 
SEER-18 in 2013 (12), was reset to the SEER rate with an upper confidence limit estimated 
from the Poisson model and a lower confidence limit estimated from SEER data. If the 
modeled upper confidence limit was lower than the SEER estimate, the SEER upper 
confidence limit was used. Likewise, because PLWH have a deficit of prostate, breast, and 
colon cancer (9, 13), we assumed that the age-specific rates of these cancer types would 
never exceed those in SEER-18.
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HOPE Model
The number of PLWH in the United States during 2006 to 2030 was estimated with the 
dynamic, compartmental HOPE model, which simulates the sexually active U.S. population 
beginning in 2006 (14, 15). The population is stratified into 195 subpopulations by 
transmission group (gay, bisexual, and other MSM [collectively referred to as MSM]; 
PWID; or heterosexuals); sex (male or female); race/ethnicity (black; Hispanic or Latino; or 
combined white and other racial/ethnic groups, of which whites comprised 89%); age group 
(13 to 17 years, 18 to 24 years, 25 to 34 years, 35 to 44 years, 45 to 64 years, or 65 years or 
older); male circumcision status (circumcised or uncircumcised); and HIV risk level (low or 
high), as defined for this model on the basis of previously published methods (16, 17). The 
force of HIV infection, or the rate at which susceptible persons acquire HIV infection, is a 
function of HIV prevalence among their partners and transmission risk from sexual and 
needle contacts with HIV-infected partners.
The total population (PLWH and susceptible persons) transitions among the 25 
compartments, which are defined by disease progression and continuum-of-care stage, and 
moves into (at age 13 years) and out of the model via aging and death. The model uses 
differential equations to represent the progression of the HIV-uninfected and HIV-infected 
populations between compartments. Differential equations in the model are solved using 
MATLAB software (MathWorks). Additional model details, including definitions of all 
subpopulations and compartments and descriptions of differential equations; force-of-
infection calculations; inputs and sources; calibration; validation; and other methods, 
assumptions, and specifications, are published in a full technical report on the HOPE model 
(14, 15). This model assumes that no new infections occur among or are caused by persons 
older than 65 years. The HOPE model has been shown to closely match published HIV 
surveillance estimates. For example, the latest 2014 estimates from the Centers for Disease 
Control and Prevention for persons aged 13 to 64 years were 1 107 700 cases for overall 
HIV prevalence and 37 600 cases for overall HIV incidence (28), and the model predictions 
were 1 042 140 and 35 761 cases, respectively.
To consider the uncertainty of the HIV prevalence for 2006 to 2030 due to the values of the 
parameters, we ran the HOPE model using 10 additional sets of values for those inputs that, 
like the set used in the base-case analysis, approximated the targeted surveillance measures. 
To generate each of the 10 sets, we went through a calibration process, which was also used 
to generate the base-case inputs. The process that was applied to calibrate the model is 
outlined in sections 11.1.1 to 11.1.4 of the published technical report (15). We report the 
range of the HIV population estimates across those runs.
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Appendix Table 1.
Description of Joinpoint Analyses and Modeling Decisions, by Cancer Site and Age Group
Variable Cases, n Significant Joinpoint (Year) Annual 
Percent 
Change (P 
Value)
Estimate 
Replaced with 
SEER 2013 Rate 
(Years)*
AIDS-defining cancer
    Kaposi sarcoma†
        MSM
            18–34 y 642 No −5.0 (P < 
0.001)
No
            35–44 y 904 No −5.2 (P < 
0.001)
No
            ≥45 y 511 No −8.0 (P < 
0.001)
No
        Non-MSM
            18–34 y 194 No −5.2 (P = 0.01) No
            35–44 y 420 No −8.8 (P < 
0.001)
No
            ≥45 y 420 No −11.3 (P < 
0.001)
No
    NHL†
        18–24 y 86 No −11.1 (P = 
0.001)
No
        25–34 y 529 No −5.1 (P < 
0.001)
No
        35–44 y 1660 Yes (2002) −6.2 (P < 
0.001)
No
        45–64 y 2403 No −9.0 (P < 
0.001)
Yes (2028–2030)
        ≥65 y 168 No −12.7 (P < 
0.001)
Yes (2014–2030)
    Cervical cancer‡
        25–34 y 75 No −8.7 (P < 
0.001)
Yes (2030)
        35–44 y 252 No −8.7 (P < 
0.001)
Yes (2027–2030)
        ≥45 y 209 No −8.7 (P < 
0.001)
Yes (2025–2030)
Non-AIDS-defining cancer
    Lung cancer†‡
        35–44 y 278 No −9.1 (P < 
0.001)
Yes (2025–2030)
        45–64 y 1857 No −5.6 (P < 
0.001)
Yes (2020–2030)
        ≥65 y 360 No −7.9 (P < 
0.001)
Yes (2011–2030)
    Prostate cancer†‡
        35–44 y 52 No 8.7 (P = 0.050) Yes (2002–2030)
        45–64 y 1116 No 3.5 (P < 0.001) Yes (2024–2030)
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Variable Cases, n Significant Joinpoint (Year) Annual 
Percent 
Change (P 
Value)
Estimate 
Replaced with 
SEER 2013 Rate 
(Years)*
        ≥65 y 381 No 1.2 (P = 0.45) No
    Anal cancer
        MSM‡
            25–34 y 58 No −2.7 (P = 
0.005)
No
            35–44 y 330 No −2.7 (P = 
0.005)
No
            ≥45 y 537 Yes (2009)§ −2.7 (P = 
0.005)
No
        Non-MSM
            25–34 y 26 No 1.4 (P = 0.32) No
            35–44 y 158 No 1.4 (P = 0.32) No
            ≥45 y 333 No 1.4 (P = 0.32) No
    Liver cancer
        PWID‡
            35–44 y 38 No 0.8 (P = 0.51) No
            45–64 y 577 No 0.8 (P = 0.51) No
            ≥65 y 48 Yes (2005)§ 0.8 (P = 0.51) No
        Non-PWID‡
            35–44 y 73 No −1.4 (P = 0.92) No
            45–64 y 350 No −1.4 (P = 0.92) No
            ≥65 y 49 No −1.4 (P = 0.92) No
    Hodgkin lymphoma‖
        18–34 y 155 No −4.4 (P < 
0.001)
No
        35–44 y 324 No −4.4 (P < 
0.001)
No
        ≥45 y 440 No −4.4 (P < 
0.001)
No
    Oral cavity/pharyngeal cancer‡
        35–44 y 105 No −1.5 (P = 
0.175)
No
        45–64 y 555 No −1.5 (P = 
0.175)
No
        ≥65 y 59 No −1.5 (P = 
0.175)
No
    Breast cancer‡
        25–44 y 206 No −1.4 (P = 0.24) No
        45–64 y 436 No −1.4 (P = 0.24) No
        ≥65 y 48 No −1.4 (P = 0.24) No
    Colon cancer†‡
        25–44 y 58 No −4.7 (P = 0.22) No
        45–64 y 325 No 0.01 (P = 0.99) No
        ≥65 y 117 No −6.0 (P = 
0.028)
No
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Variable Cases, n Significant Joinpoint (Year) Annual 
Percent 
Change (P 
Value)
Estimate 
Replaced with 
SEER 2013 Rate 
(Years)*
    All other cancer types†
        18–34 y 269 No −5.3 (P = 
0.002)
No
        35–44 y 1019 No −3.1 (P = 
0.001)
No
        45–64 y 3379 No −2.0 (P < 
0.001)
No
        ≥65 y 579 No −3.4 (P = 
0.008)
No
MSM = men who have sex with men; NHL = non-Hodgkin lymphoma; PLWH = persons living with HIV; PWID = persons 
who inject drugs; SEER = Surveillance, Epidemiology, and End Results.
*
For types of cancer known to be elevated in PLWH, we assumed a priori that future cancer rates would never be lower 
than rates observed in the general population. Therefore, any projected rate that was lower than the 2013 age-specific rate in 
SEER-18 data (as a proxy for the U.S. general population) was reset to the SEER rate. Likewise, because PLWH have a 
lower risk for prostate, breast, and colon cancer for unclear reasons, we assumed that the age-specific rates of these types of 
cancer would never exceed those in SEER-18.
†
Time trends differed significantly across age groups, so trends were projected separately for each age group.
‡
The cancer incidence rates in the youngest age group(s) were assumed to be 0 because of the limited number of reported 
cases of cervical cancer (n = 1), anal cancer in MSM (n = 2), anal cancer in non-MSM (n = 0), lung cancer (n = 10), liver 
cancer in PWID (n = 0), liver cancer in non-PWID (n = 2), oral cavity/pharyngeal cancer (n = 7), prostate cancer (n = 2), 
breast cancer (n = 2), and colon cancer (n = 0).
§A joinpoint was identified, but when the calendar years were limited, data were too sparse for forecasting.
‖2000 excluded because of extreme estimates.
Appendix Table 2.
Characteristics of Modeled Adult U.S. HIV Population in 2010, 2020, and 2030*
Characteristic 2010 (n = 1 127 669) 2020 (n = 1 161 947) 2030 (n = 1 091 827)
Sex
    Male 846 197 (75.0) 879 868 (75.7) 838 770 (76.8)
    Female 281 472 (25.0) 282 079 (24.3) 253 057 (23.2)
Age group
    18–24 y 73 130 (6.5) 40 260 (3.5) 21 550 (2.0)
    25–34 y 212 100 (18.8) 157 330 (13.5) 111 310 (10.2)
    35–44 y 301 590 (26.7) 254 290 (21.9) 204 400 (18.7)
    45–64 y 444 710 (39.4) 520 050 (44.8) 520 470 (47.7)
    ≥65 y 96 139 (8.5) 190 017 (16.4) 234 097 (21.4)
Race/ethnicity
    Non-Hispanic black 481 535 (42.7) 472 273 (40.6) 419 535 (38.4)
    Hispanic 218 971 (19.4) 228 199 (19.6) 216 506 (19.8)
    Non-Hispanic white/other 427 163 (37.9) 461 475 (39.7) 455 786 (41.7)
Risk group
    MSM 624 456 (55.4) 677 332 (58.3) 665 471 (61.0)
    PWID 193 630 (17.2) 174 103 (15.0) 148 579 (13.6)
    Heterosexual 309 583 (27.5) 310 512 (26.7) 277 777 (25.4)
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*Values are numbers (percentages).
MSM = men who have sex with men; PWID = persons who inject drugs.
Appendix Table 3.
Minimum and Maximum Estimates for Adult U.S. HIV Population, by Calendar Year
Year Estimated PLWH, n Minimum Estimate, n Maximum Estimate, n
2006 1 063 089 1 058 806 1 063 091
2007 1 083 294 1 080 005 1 085 508
2008 1 100 540 1 098 408 1 107 386
2009 1 115 194 1 114 485 1 127 652
2010 1 127 669 1 122 937 1 143 608
2011 1 138 033 1 135 849 1 154 345
2012 1 146 495 1 142 227 1 164 294
2013 1 152 985 1 145 083 1 164 667
2014 1 157 701 1 150 285 1 170 579
2015 1 160 646 1 150 527 1 174 673
2016 1 163 729 1 146 365 1 178 523
2017 1 165 314 1 141 017 1 181 120
2018 1 165 445 1 134 735 1 182 647
2019 1 164 345 1 127 537 1 183 059
2020 1 161 947 1 119 647 1 182 577
2021 1 158 499 1 111 107 1 181 218
2022 1 154 081 1 102 013 1 179 068
2023 1 148 743 1 092 395 1 176 197
2024 1 142 497 1 082 290 1 172 599
2025 1 135 609 1 071 792 1 168 422
2026 1 127 914 1 060 843 1 163 570
2027 1 119 687 1 049 509 1 158 147
2028 1 110 830 1 037 915 1 152 268
2029 1 101 618 1 025 998 1 145 881
2030 1 091 827 1 013 812 1 139 042
PLWH = persons living with HIV.
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Figure 1. Age-standardized cancer rates for U.S. adults with HIV.
Rates were standardized to the 2010 U.S. HIV population by age group. Rates for cervical 
and breast cancer were restricted to women, and rates for prostate cancer were restricted to 
men. ADC = AIDS-defining cancer; NADC = non–AIDS-defining cancer; PLWH = persons 
living with HIV.
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Figure 2. Estimated number of adults living with HIV in the United States during 2006–2030, by 
age group.
Age groups were 18–24 y, 25–34 y, 35–44 y, 45–64 y, and ≥65 y.
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Figure 3. Estimated number of incident diagnoses of ADC and NADC in adults living with HIV 
in the United States during 2006–2030, stratified by age.
Black segments represent ADC, green segments represent NADC, dark bars represent cancer 
cases among persons aged ≥45 y, and light bars represent cancer cases among those aged 
<45 y. ADC = AIDS-defining cancer; NADC = non–AIDS-defining cancer.
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Figure 4. Estimated cancer burden (incident cancer diagnoses) among adults living with HIV in 
the United States, by cancer type, in 2010, 2020, and 2030.
KS = Kaposi sarcoma; NHL = non-Hodgkin lymphoma.
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Figure 5. Estimated cancer burden (incident cancer diagnoses) among adults living with HIV in 
the United States, by cancer type, in 2012 and 2030.
Cancer burden estimates for 2030 were calculated 3 different ways: using the 2030 projected 
cancer incidence rates and 2030 projected age structure, using the 2012 modeled cancer 
incidence rates and 2030 projected age structure, and using the 2030 projected cancer 
incidence rates and 2012 modeled age structure. KS = Kaposi sarcoma; NHL = non-
Hodgkin lymphoma.
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Table.
Estimated Cancer Burden and Uncertainty Estimates in U.S. Adults With HIV During 2010, 2020, and 2030*
Cancer type Estimated Burden (Uncertainty Estimate)
2010 2020 2030
Total 8150 (7280–9210) 7490 (5890–9490) 6690 (4950–9060)
AIDS-defining cancer 2730 (2440–3100) 1340 (990–1790) 720 (510–1070)
    Non-Hodgkin lymphoma 1490 (1350–1660) 750 (590–940) 450 (360–580)
    Kaposi sarcoma 1120 (990–1290) 540 (370–770) 240 (130–450)
    Cervical cancer 120 (100–140) 50 (30–70) 30 (20–30)
Non–AIDS-defining cancer 5420 (4850–6120) 6150 (4900–7700) 5980 (4430–7990)
    Lung cancer 830 (750–920) 910 (850–950) 1030 (940–1090)
    Prostate cancer 750 (680–840) 1340 (1060–1660) 1590 (1240–1820)
    Anal cancer 580 (510–670) 550 (410–720) 450 (290–700)
    Liver cancer 360 (300–430) 460 (360–590) 480 (360–630)
    Hodgkin lymphoma 300 (260–350) 200 (140–270) 120 (70–200)
    Oral cavity/pharyngeal cancer 250 (220–290) 320 (250–390) 340 (260–430)
    Breast cancer 220 (190–270) 260 (210–330) 260 (200–330)
    Colon cancer 220 (180–270) 230 (150–380) 200 (110–420)
    Other 1910 (1760–2080) 1880 (1450–2410) 1510 (960–2380)
*Cancer burden is defined as the number of incident cancer diagnoses. Results were rounded to the nearest 10 cases of cancer.
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